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Summary Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening dis-
order that occurs in late pregnancy or the early puerperium despite optimal medical therapy.cardiomyopathy;
Prolactin;
Bromocriptine;
Heart failure
Recently, oxidative stress-mediated generation of antiangiogenic and proapoptotic 16-kDa pro-
lactin, and subsequent impaired cardiac microvascularization have been related to PPCM. In
turn, prolactin blockade with bromocriptine has been proven successful in preventing the onset
of PPCM in mice and in patients at high risk for the disease. Here, we report the efﬁcacy of
bromocriptine for treatment of a patient with PPCM.
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eripartum cardiomyopathy (PPCM) is a rare but potentially
ife-threatening disorder occurring in late pregnancy or the
arly puerperium despite optimal medical therapy [1]. Diag-
osis of PPCM is based on 4 primary diagnostic criteria [2]:
a) development of cardiac failure in the last month of preg-
ancy or within 5 months of delivery; (b) absence of an
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dentiﬁable cause of cardiac failure; (c) absence of recog-
izable heart disease before the last month of pregnancy;
d) left ventricular systolic dysfunction with left ventricular
jection fraction of <45% by echocardiography. The treat-
ent is empirical and restricted to standard heart failure
herapy, and, in the most severe cases, biventricular assist
ystems or heart transplantation.
Little is known about the pathophysiology of PPCM, and
here are few suitable animal models for studying the dis-
ase. There has been speculation about the involvement
f inﬂammation, myocarditis, autoimmune reactions, and
poptosis. More recently, oxidative stress-mediated gener-
tion of antiangiogenic and proapoptotic 16-kDa prolactin,
nd subsequent impaired cardiac microvascularization have
een related to PPCM [3].
Published by Elsevier Ireland Ltd. All rights reserved.
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aFigure 1 (a) Electrocardiography at admission showed sinu
Electrocardiography 6 months after discharge showed sinus rhy
We report the efﬁcacy of bromocriptine for treatment of
a patient with PPCM.
Case report
A 21-year-old woman at approximately 38 weeks’ gesta-
tion was admitted to our hospital with acute shortness
of breath and chest tightness [New York Heart Association
(NYHA) functional class IV], which she reported ﬁrst noticing
1 week before. She had no history of hypertension, diabetes
mellitus, smoking, or dyslipidemia. She had no pre-existing
cardiac disease, pregnancy-induced hypertension, protein-
uria during her pregnancy, exposure to cardiotoxic agents,
or positive family history of pregnancy-related heart dis-
ease. Physical examination revealed a blood pressure of
141/103mmHg, regular heart rate of 154 beats/min, respi-
ratory rate of 45 breaths/min, and temperature of 37.3 ◦C.
The oxygen saturation was 94% while the patient was breath-
ing oxygen at 3 l/min by nasal cannula. There was pitting
edema (2+) of the feet and legs. The brain natriuretic pep-
tide (BNP) level was markedly elevated to 2440 pg/ml, and
creatine kinase was up to 487mU/ml (Table 1). The level
of total prolactin was 51.38 ng/ml (reference: <30.54 ng/ml
C
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Table 1 Plasma levels of biochemical parameters.
At Cesarean section 1 month
Bromocriptine − +
BNP (pg/ml) 2440 44.8
Prolactin (ng/ml) 58.2 <0.5
CRP (mg/l) 1.88 0.08
CK (mU/ml) 487 26
BNP, brain natriuretic peptide; CRP, C-reactive protein; CK, creatine kihycardia, poor R in V2 and V3 leads and ﬂat T waves. (b)
nd positive T waves.
n nonpregnant woman). Other laboratory parameters were
ormal. Electrocardiography (ECG) showed sinus tachy-
ardia, poor R waves in V2-3, and ﬂat T waves in all
eads (Fig. 1a). Chest radiography disclosed cardiomegaly,
nterstitial pulmonary edema, and small bilateral pleural
ffusions. Echocardiography revealed that the left ventri-
le was dilated (left ventricular diastolic dimension: 58mm)
nd diffusely hypokinetic, without segmental wall-motion
bnormalities and an ejection fraction of 21% (Table 2).
he left ventricular wall thickness was 8.7mm. There was
oderate mitral regurgitation with left atrial enlargement.
evere tricuspid regurgitation existed and the estimated
ight ventricular systolic pressure was 38mmHg when the
ight atrial pressure was assumed to be 10mmHg. The infe-
ior vena cava was dilated and the collapsibility was poor.
here was no pericardial effusion.
Since termination of pregnancy was considered neces-
ary to prohibit deterioration of PPCM, and since she showed
n immature cervix, we decided to perform an emergent
esarean section under general anesthesia. At the 1st hos-
ital day, she abdominally gave birth to a female infant
eighing 2980 g with a 5-min Apgar score of 8. After the
esarean section, conventional treatment for heart fail-
re (diuretics, an angiotensin-converting enzyme inhibitor,
3 months 6 months 12 months
+ − +
78.2 38.3 16.2
<0.5 22.9
0.25
52 52 41
nase.
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Table 2 Echocardiographic parameters.
At Cesarean section 1 month 3 months 6 months 12 months
Bromocriptine − + + − −
EF (%) 21 32 45 49 58
LVd (mm) 58 53 48 47 49
LAd (mm) 42 33 27 31 38
IVST (mm) 8.7 10 7.3 7.4 8
PWT (mm) 9.6 11 7.3 7.4 8
MR Moderate Moderate Mild Mild —
TR Severe Mild Mild Mild Mild
PA pressure (mmHg) 38 33 41 30 33
DcT 193 222 157 195
E/A 1.5 1.77 1.31 1.67
LV Tei index 0.89 0.49 0.59 0.50
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mEF, ejection fraction; LVd, left ventricular diastolic diameter; LA
posterior wall thickness; MR, mitral regurgitation; TR, tricuspid reg
time; E/A, peak velocity ratio of the early diastolic to the atrial s
nd a beta-blocker) was started. The patient’s condition
mproved, but the ejection fraction of the left ventricle was
ower than 30%. After obtaining informed consent, includ-
ng a full explanation of potential complications, from the
atient on the 7th hospital day, treatment with bromocrip-
ine was started. In parallel with bromocriptine treatment,
he left ventricular function and heart failure symptoms
mproved, accompanied by a decrease of BNP (Table 1).
romocriptine was continued for 3 months at 5mg/day.
hallium myocardial scintigraphy at the 15th hospital day
howed normal uptake in both the early and delayed (4 h
fter the early) imaging. At 6 months’ follow-up, the patient
as in NYHA functional class I. An ECG showed that the R
aves in V2 and V3 (Fig. 1b) were recovered. The LV function
nd dimensions had further improved (Table 2), and mitral
alve regurgitation was only mild.
iscussion
lthough the pathophysiology of PPCM is largely unknown,
ilﬁker-Kleiner et al. recently published an interesting
aper that sheds new light on the pathogenesis of this
isease [3]. In brief, signal transducer and activator of
ranscription 3 (STAT3) knock-out mice readily develop
PCM. STAT3 has several cardioprotective functions in the
eart, including protective effects against oxidative stress.
xidative stress and the release of cathepsin D from car-
iomyocytes can result in cleavage of the 23 kDa form of
rolactin into an antiangiogenic and proapoptotic 16 kDa
orm. The authors showed that this 16 kDa form induced car-
iomyopathy in these mice. Interestingly, this effect could
e abolished by bromocriptine administration. In a subse-
uent clinical study of 12 women with previous PPCM, 6 were
reated prophylactically with bromocriptine. In the treated
roup, all women survived with preserved left ventricular
unction, whereas all women in the control group had dete-
iorated left ventricular function and 3 women died.
In the present report, we showed that bromocriptine was
ffective for the treatment of a patient with acute PPCM.
ven though there have been three case reports [4—6] show-
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rft atrial diameter; IVST, intraventricular septum thickness; PWT,
ation; PA, pressure, pulmonary artery pressure; DcT, deceleration
ic wave in the transmitral ﬂow; LV, left ventricular.
ng that bromocriptine improved the clinical symptoms of
PCM, its indication remains controversial [7,8]. It has also
een reported that patients with an initially low ejection
raction and ventricular dilatation recovered normal cardiac
unction under the combination of a beta-blocker and an
ngiotensin-converting enzyme inhibitor.
During pregnancy, maternal serum prolactin levels rise
rogressively. After delivery, prolactin levels remain ele-
ated and fall gradually toward the normal range during a
—4-week interval in non-breast-feeding mothers. For this
eason, the duration of bromociptione treatment is from 6
o 12 weeks [3—6].
Long-term survival of PPCM has been reported to be
etween 85% and 94% at 5 years [1]. This is probably due
o the high rate of spontaneous recovery of left ventricular
unction in PPCM. However, women with PPCM with a base-
ine left ventricular ejection fraction of 25% or less at the
ime of diagnosis have been shown to have a poor long-term
utcome, and 57% of these women will subsequently require
ardiac transplant [9].
In light of discoveries regarding the pathology and
ecretion pattern of prolactin in this disease, bromocrip-
ine may be a causative therapeutic option in severe
eart failure patients with PPCM. In these patients,
t is too risky to administer conventional heart failure
reatment (angiotensin-converting enzyme inhibitors and
eta-blockers) and wait several months for a possible
mprovement. Moreover, adverse effects of bromocriptine
t this dosage and for this treatment duration are rare.
A previous report showed that bromocriptine treatment
ad positive effects in heart failure patients without PPCM
10]. In another study, bromocriptine decreased plasma
orepinephrine levels and improved the hemodynamic pro-
le. It is possible that a multifactorial role of bromocriptine
ight ultimately account for its beneﬁcial effects [4].
The present observations were limited for several rea-ons. We did not evaluate oxidative stress of the heart,
elease of cathepsin D, or the levels of 16 kDa prolactin,
ostly due to the difﬁculties in checking these parameters
uring the acute phase of PPCM. In addition, it has been
eported that some PPCM patients recover spontaneously,
Bromocriptine treatment for peripartum cardiomyopathy
so we cannot rule out such an effect in the present case.
Finally, despite our encouraging results, a randomized trial
will be needed to deﬁnitively demonstrate the efﬁcacy of
bromocriptine in the treatment of PPCM.
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